Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Pharmacokinetics of BI 3034701 (C-14) in Healthy Male Volunteers
NCT07708493Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 3034701 in obesity, sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [14C]-radioactivity excreted in urine at Day 50, Fraction of [14C]-radioactivity excreted in faeces at Day 50 and 2 more. Started Aug 2026; status: completed.
02
Drugs
BI 3034701
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07708493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708493.